SCHEMBL6877267

SCHEMBL6877267

O=C/C=C/c1csc(-c2ccccn2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.43
NPC1 O15118 4/20 0.43
RAB9A P51151 4/20 0.43
MAPT P10636 4/20 0.43
GLA P06280 1/20 0.43
LMNA P02545 4/20 0.41
ALDH1A1 P00352 2/20 0.41
TRPA1 O75762 1/20 0.41
ALOX5 P09917 1/20 0.41
MAPK1 P28482 1/20 0.41
CYP1A2 P05177 1/20 0.37
POLB P06746 1/20 0.37
CCR1 P32246 1/20 0.37
CCR5 P51681 1/20 0.37
CCR8 P51685 1/20 0.37
METAP1 P53582 1/20 0.37
BLM P54132 1/20 0.37
HIF1A Q16665 1/20 0.37
DOHH Q9BU89 1/20 0.37
P4HTM Q9NXG6 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6877273 1.00 KDM4E (0.43) KDM4ENPC1RAB9AMAPTGLA
SCHEMBL6851830 0.84 KDM4E (0.48) KDM4ENPC1RAB9AMAPTGLA
SCHEMBL6851064 0.82 KDM4E (0.46) KDM4ENPC1RAB9AMAPTGLA
SCHEMBL6876939 0.81 ALDH1A1 (0.37) KDM4EMAPTLMNAALDH1A1TRPA1
SCHEMBL6876943 0.81 ALDH1A1 (0.37) KDM4EMAPTLMNAALDH1A1TRPA1
SCHEMBL6853984 0.79 KDM4E (0.43) KDM4ENPC1RAB9AMAPTGLA
SCHEMBL6852683 0.79 PIM2 (0.35) KDM4ELMNAALDH1A1TRPA1ALOX5
SCHEMBL6853980 0.79 KDM4E (0.43) KDM4ENPC1RAB9AMAPTGLA
SCHEMBL6852697 0.79 PIM2 (0.35) KDM4ELMNAALDH1A1TRPA1ALOX5
SCHEMBL6874913 0.75 CYP2A6 (0.40) KDM4ENPC1RAB9AMAPTGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6825170-B2 ERYTHROMYCIN TYPE MACROLIDE WITH A FUSED OXAZOLONE RING ORTHO-MCNEIL PHARMACEUTICAL, INC. 2004-11-30 US disclosed
US-20030220272-A1 6-O-acyl ketolide antibacterials ORTHO-MCNEIL PHARMACEUTICAL, INC. 2003-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220272-A1 6-O-acyl ketolide antibacterials Q6ZSR9, ACSL6, RPS4Y1 KDM4E 18/4885NPC1 2962/4885RAB9A 982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.